Study of XL999 in Patients With Multiple Myeloma
This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with relapsed or refractory multiple myeloma. XL999 is a small molecule inhibitor of cellular factors including VEGFR, PDGFR, and FGFR that may be involved in multiple myeloma.
Multiple Myeloma
DRUG: XL999
Response rate, Inclusion of subject until disease progression|Safety and tolerability, Inclusion until 30 days post last treatment
Duration of response, Inclusion until disease progression|Progression-free survival, Inclusion until disease progression|Overall survival, Inclusion until 180-day Follow-up or death
This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with relapsed or refractory multiple myeloma. XL999 is a small molecule inhibitor of cellular factors including VEGFR, PDGFR, and FGFR that may be involved in multiple myeloma.